Elena Bartoloni Selected Research

Therapeutics

11/2021	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort.
1/2021	Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine'.
1/2021	COVID-19: the new challenge for rheumatologists. One year later.
1/2020	COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy.
1/2019	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response.
1/2018	Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality?
1/2018	Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases.
7/2015	Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry.
1/2015	Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.
12/2014	Drugs in induction and treatment of idiopathic inflammatory myopathies.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elena Bartoloni Research Topics

Disease

9	Rheumatoid Arthritis 10/2022 - 09/2012
8	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 10/2010
8	COVID-19 01/2021 - 01/2020
6	Myositis (Idiopathic Inflammatory Myopathies) 10/2022 - 12/2014
5	Lymphoma (Lymphomas) 01/2022 - 11/2015
5	Rheumatic Diseases (Rheumatism) 01/2021 - 08/2012
5	Arthritis (Polyarthritis) 11/2019 - 01/2013
4	Systemic Lupus Erythematosus (Libman-Sacks Disease) 07/2021 - 02/2013
4	Adult-Onset Still's Disease 01/2020 - 01/2017
3	Hypertension (High Blood Pressure) 11/2021 - 01/2018
3	Infections 01/2021 - 07/2015
3	Virus Diseases (Viral Diseases) 01/2021 - 01/2020
3	Inflammation (Inflammations) 01/2020 - 07/2012
3	Interstitial Lung Diseases (Interstitial Lung Disease) 11/2019 - 08/2015
3	Antisynthetase syndrome 11/2019 - 08/2015
3	Osteoarthritis 01/2019 - 04/2016
3	Atherosclerosis 01/2019 - 10/2010
2	Neoplasms (Cancer) 10/2022 - 01/2017
2	Purpura 01/2021 - 11/2015
2	Cryoglobulinemia 01/2021 - 01/2017
2	Hypergammaglobulinemia (Hyperimmunoglobulinemia) 11/2015 - 12/2014
1	Inclusion Body Myositis 10/2022
1	Skin Manifestations 10/2022
1	Calcinosis 10/2022
1	Dermatomyositis (Dermatopolymyositis) 10/2022
1	Lupus Nephritis 11/2021
1	Musculoskeletal Diseases (Musculoskeletal Disease) 11/2021
1	Proteinuria 11/2021
1	Acquired Immunodeficiency Syndrome (AIDS) 02/2021
1	Critical Illness (Critically Ill) 01/2021
1	Vasculitis (Vasculitides) 01/2021
1	Pathologic Processes 01/2021
1	Sarcoma (Soft Tissue Sarcoma) 01/2021
1	Leukopenia 01/2021
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 07/2020
1	Thrombosis (Thrombus) 07/2020
1	Sialadenitis 07/2020
1	Hyperferritinemia 01/2020
1	Iron Overload 01/2020
1	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 01/2020
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2020
1	Macrophage Activation Syndrome 01/2020
1	Fibrosis (Cirrhosis) 01/2020
1	Septic Shock (Toxic Shock Syndrome) 01/2020
1	Lymphopenia (Lymphocytopenia) 01/2020

Drug/Important Bio-Agent (IBA)

12	AntibodiesIBA 10/2022 - 09/2012
5	AutoantibodiesIBA 10/2022 - 02/2017
4	Rheumatoid FactorIBA 07/2020 - 09/2012
3	Proteins (Proteins, Gene)FDA Link 10/2022 - 08/2015
3	Ligases (Synthetase)IBA 10/2022 - 03/2017
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2012
3	belimumabIBA 11/2021 - 01/2020
3	GlucocorticoidsIBA 07/2021 - 07/2012
3	Pharmaceutical PreparationsIBA 02/2021 - 12/2014
3	CytokinesIBA 01/2020 - 10/2010
3	Peptides (Polypeptides)IBA 01/2020 - 09/2012
3	InterleukinsIBA 01/2020 - 01/2017
3	Interleukin-17 (Interleukin 17)IBA 01/2019 - 01/2013
2	C-Reactive ProteinIBA 10/2022 - 11/2021
2	Rituximab (Mabthera)FDA Link 07/2021 - 07/2015
2	Immunosuppressive Agents (Immunosuppressants)IBA 07/2021 - 01/2020
2	Colchicine FDA LinkGeneric 01/2021 - 01/2020
2	Immunomodulating AgentsIBA 01/2021 - 01/2020
2	Biological ProductsIBA 01/2021 - 01/2017
2	Interleukin-6 (Interleukin 6)IBA 05/2020 - 01/2020
2	Antirheumatic Agents (DMARD)IBA 01/2020 - 01/2020
2	Interleukin-1 (Interleukin 1)IBA 01/2020 - 01/2017
2	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2020 - 01/2019
2	CryoglobulinsIBA 01/2017 - 11/2015
2	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2013 - 10/2010
2	cyclic citrullinated peptideIBA 01/2013 - 09/2012
1	RNA (Ribonucleic Acid)IBA 10/2022
1	LDL CholesterolIBA 11/2021
1	CreatinineIBA 11/2021
1	Monoclonal AntibodiesIBA 01/2021
1	GlobulinsIBA 01/2021
1	Neutralizing AntibodiesIBA 01/2021
1	Intravenous Immunoglobulins (IVIG)FDA Link 01/2021
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2021
1	AntigensIBA 01/2021
1	Complement System Proteins (Complement)IBA 01/2021
1	Janus Kinase InhibitorsIBA 01/2021
1	Protein-Arginine Deiminase Type 4IBA 01/2021
1	Janus KinasesIBA 01/2021
1	Peptide LibraryIBA 01/2021
1	Immunoglobulin G (IgG)IBA 07/2020
1	Immunoglobulin M (IgM)IBA 07/2020
1	Antiphospholipid AntibodiesIBA 07/2020
1	Eosine Yellowish-(YS) (Eosin)IBA 07/2020
1	Thymic Stromal LymphopoietinIBA 07/2020
1	Immunoglobulin A (IgA)IBA 07/2020
1	IronIBA 01/2020
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2020
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020
1	Ferritins (Ferritin)IBA 01/2020
1	Transfer RNA (tRNA)IBA 11/2019
1	Amino Acyl-tRNA Synthetases (Aminoacyl-tRNA Synthetase)IBA 11/2019

Therapy/Procedure

12	Therapeutics 11/2021 - 10/2010
2	Precision Medicine 01/2022 - 02/2021
1	Mediterranean Diet 11/2021